NPPA hikes 21 formulations’ prices by 50%
The National Pharmaceuticals Pricing Authority (NPPA) invoked paragraph 19 of the Drug Prices Control Order to grant a 50% increase in the prices of 21 drug formulations. With the cost of raw material imported from China increasing 50-200%, pharma groups had approached the government to invoke extraordinary powers and increase the prices of drugs.
Avoid metals in long term, go for India focused pharma cos: Sudip Bandyopadhyay
The uncertainties on the back of the tariff war have not ended, says Inditrade Cap group chairman.
Share market update: Pharma shares gain; Glenmark Pharma up 2%
The Nifty Pharma index was trading 0.32 per cent up at 7985.8 .
Financial, consumer and pharma stocks to drive market over next 2 years: Mahesh Patil
The midcap index has started to relatively outperform a bit but it is still early days.
Share market update: Nifty Pharma index up; Glenmark Pharma rises 2%
The Nifty Pharma index was trading 0.91 per cent up at 8040.65 .
Share market update: Nifty Pharma index down; Dr. Reddy's Lab dips 3%
The Nifty Pharma index was trading 0.32 per cent down at 8019.95 .
Buy Sun Pharmaceutical Industries, target Rs 455: Kunal Bothra
Buy Sun Pharmaceutical Industries Ltd. at a price target of Rs 455.0 and a stoploss at Rs 425 from entry point.
Pharma companies seek hike in drug rates under price control
Chinese API imports turn 200% costlier, making production costlier in India. Over 70% of the country’s total bulk drug requirement comes from China. These bulk drugs or active pharmaceutical ingredients (API) are used in producing medicines, including essential items like antibiotics, vitamins and folic acid.
Share market update: Nifty Pharma index up; Piramal Enterprises gains 1%
The Nifty Pharma index was trading 0.23 per cent up at 7958.4 .
Amit Rajan on why pharma MNCs are beating Indian counterparts
Patent protection, ban on fixed dose combinations among factors helping pharma MNCs
Hemang Jani on why telecom, pharma & penny stocks are showing momentum now
FMCG, some private sector banks and even metal names are seeing corrections.
Most foreign funds not massively overweight on India: Ayon Mukhopadhyay, IIFL Securities
Reforms in the NBFC sector can increase the GDP by 1 to 2%, says Mukhopadhyay.
Why this fund manager is betting against consumption
We are cautious on the consumer space, where we think valuations are stretched specifically with the consumer staples pack. Between the consumer staples and consumer discretionary pack, there is still some upside left on the consumer discretionary side. But we are fairly cautious on the staples pack. On the consumption basket, we continue to be cautious on the auto sector.
Sell Aurobindo Pharma, price target Rs 410: Arun Kumar
The analyst suggested a stoploss at Rs 447.
Kunal Bothra’s 3 high momentum picks for next week
The market breadth has been improving and not just in terms of the advance decline ratio. Earlier, the rally had started from the low beta or defensive stocks like pharma and the IT stocks. Then in the second half of the week, we saw the metals as well as PSU banking pack pick up quite a bit of a pace.
Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service